$NVCR 8-K earnings — Q2 FY26

EPS of -$0.13 missed consensus by $0.03 (30% miss). Revenue of $183.6M beat estimates, up 16% YoY on record 5,128 active patients. The headline net loss masks a $4.9M tariff refund boosting gross margin to 78% and $2.8M one-time revenue benefits; strip these out, operating trends are weaker.

Revenue beat and patient growth offset EPS miss, but one-time boosts add caution.